8247 — BioSino Bio-technology and Science Income Statement
0.000.00%
Last trade - 00:00
- HK$92.61m
- HK$235.06m
- CNY289.07m
- 21
- 66
- 32
- 30
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 397 | 325 | 348 | 373 | 289 |
Cost of Revenue | |||||
Gross Profit | 168 | 111 | 144 | 146 | 127 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 496 | 314 | 333 | 354 | 313 |
Operating Profit | -98.5 | 11.3 | 15.4 | 18.8 | -23.6 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -115 | 2.15 | 6.41 | 18.5 | -17.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -118 | -0.706 | 3.16 | 14.2 | -19.2 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -110 | 2.72 | -1.14 | 8.11 | -11.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -110 | 2.72 | -1.14 | 8.11 | -11.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.201 | -0.021 | -0.005 | 0.06 | -0.078 |
Dividends per Share |